NL-OMON24969招募中不适用
A phase 1B study of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies
niversity Medical Center Erasmus Medical Center Rotterdam The Netherlands0 个研究点目标入组 82 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 82
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Inclusion criteria stratum 1
- •Histologically or cytologically confirmed diagnosis of ALCL
排除标准
- •Other serious illnesses or medical conditions
研究者
相似试验
进行中（未招募）
1 期
Study into the safety and activity of the drug Crizotinib for children with malignant tumorsEUCTR2015-005437-53-NLErasmus Medical Center71
进行中（未招募）
1 期
Study evaluating the safety and activity of the drug Crizotinib for children with malignant tumorsChildren and young adults with malignancies carrying a genetic alteration of ALK, MET or ROS1 with no better treatment options according to the current (inter)national guidelinesEUCTR2015-005437-53-DEErasmus Medical Center82
进行中（未招募）
1 期
Study into the safety and activity of the drug Crizotinib for children with malignant tumorsEUCTR2015-005437-53-DKErasmus Medical Center71
招募中
2 期
A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies;Study ITCC 053malignancies10027655cancerNL-OMON54812Erasmus MC, Universitair Medisch Centrum Rotterdam20
进行中（未招募）
1 期
Study into the safety and activity of the drug Crizotinib for children with malignant tumorsMalignancies carrying a genetic alteration of ALK, MET or ROS1EUCTR2015-005437-53-IEErasmus Medical Center82